NOXXON Pharma AG has appointed Frank Morich as chief executive officer, replacing Sven Klussmann.
Dr Klussmann, who has been serving as both CEO and chief scientific officer, will henceforth be CSO.
Dr Morich joins NOXXON from Innogenetics NV of Belgium.
Based in Berlin, Germany, NOXXON develops biostable aptamers, which are substances based on mirror image nucleic acids. The company calls these substances Spiegelmers, after the German word, Spiegel, for mirror.
Source:
NOXXON Pharma press release, 7 January 2008
Copyright 2008 Evernow Publishing Ltd